Dr. Huertas has been active in the pharmaceutical industry for nearly 20 years and is experienced in research, development, medical affairs, and regulatory affairs concerning therapeutics for human genetic and metabolic diseases. Dr. Huertas’ last position was with Precision Medicine as Clinical Lead and Head of Precision Medicine for Rare Diseases at Pfizer Worldwide Research & Development. Dr. Huertas has extensive experience dealing with and participating in negotiations with regulatory authorities in the US (FDA), EU (EMA), Japan (PMDA), and throughout Latin America. He led the clinical team that filed for approval of and registered Fabrazyme (agalsidase beta) in the United States, Europe, and Japan. Dr. Huertas is a graduate of Stanford University (MS, Biochemistry), Harvard University (PhD, Cell and Developmental Biology), the Program in Health Sciences and Technology between Harvard Medical School and the Massachusetts Institute of Technology (MD), and the Sloan School of Management at the Massachusetts Institute of Technology (MS, Management). He trained in Internal Medicine, Rheumatology, and Palliative Care at Massachusetts General Hospital.